Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a progressive clinical-stage biotechnology company committed to developing transformative therapies targeting neurodegenerative and lung diseases. The company leverages innovative drug-delivery technologies to create novel treatments aimed at improving patient outcomes.
Key to Tiziana's portfolio are two prominent compounds: Milciclib and Foralumab. Milciclib, an inhibitor of cyclin-dependent kinases, is in Phase II clinical trials for thymic carcinoma, aiming to provide new hope for patients who have exhausted chemotherapy options. Foralumab, noted for being the only fully human-engineered anti-CD3 monoclonal antibody, is in various stages of clinical development for multiple sclerosis, autoimmune, and inflammatory diseases.
In a significant advancement, Tiziana recently reported positive clinical outcomes from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS). Intranasal administration of Foralumab led to remarkable improvement in fatigue symptoms in 70% of patients over six months, as measured by the Modified Fatigue Impact Scale (MFIS). These results signify a groundbreaking step in addressing an unmet need in MS treatment.
The company's commitment to innovation is backed by strategic partnerships with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital. Tiziana’s leadership team brings extensive experience in drug development and commercialization, ensuring a firm trajectory toward regulatory approvals and market entry.
Moreover, Tiziana’s pipeline includes potential therapies for conditions like ALS, Alzheimer's, and Crohn's Disease, underscoring its dedication to tackling a broad spectrum of debilitating conditions. The company’s forward-looking approach aims to revolutionize treatment paradigms through enhanced drug delivery systems that promise increased efficacy and reduced side effects.
With a robust clinical pipeline, strategic collaborations, and innovative technologies, Tiziana Life Sciences Ltd. remains at the forefront of biopharmaceutical research, poised to make significant strides in the field of immunomodulation therapies.
Tiziana Life Sciences (TLSA) announced a positive update regarding its treatment for secondary progressive multiple sclerosis (SPMS) using intranasal foralumab. The FDA has allowed enrollment of a second patient in the clinical trial, following favorable data from the first patient after three months of treatment, indicating safety and a positive response. Tiziana plans to expand its clinical trials in 2022 to address other conditions such as Crohn's Disease and Type 1 Diabetes. The ongoing monitoring of patient responses is expected to provide further insights by April 2022.
Tiziana Life Sciences (Nasdaq: TLSA) announced participation at the virtual Biotech Showcase Conference on January 10-12 and 17-19, 2022. Senior management will present and be available for one-on-one meetings throughout the event. Tiziana focuses on innovative drug delivery methods, including nasal, oral, and inhalation routes, to enhance immunotherapy efficacy and safety. Their lead candidates include intranasal foralumab and milciclib, both showing promising clinical results. For more details about the conference, registration is available online.
Tiziana Life Sciences plc has restructured its corporate framework by establishing Tiziana Life Sciences Ltd as its new parent company. This change, formalized on October 20, 2021, involved a two-for-one Share Capital Consolidation, allowing shareholders to maintain their ownership proportions. The newly consolidated shares commenced trading on NASDAQ on the same date. Tiziana continues its focus on developing innovative therapeutics for diseases including cancer, inflammation, and infections, notably progressing with its anti-CD3 monoclonal antibody, Foralumab.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced a significant corporate restructuring, establishing Tiziana Life Sciences Ltd as the new parent company, effective October 20, 2021. The scheme of arrangement has been sanctioned by the Court, and the Old Tiziana shares will be delisted on October 21, 2021. Following a two-for-one share capital consolidation, the new shares are set to begin trading on NASDAQ. Tiziana specializes in innovative therapeutics for oncology and autoimmune diseases, with upcoming Phase 2 trials for its lead drug, Foralumab.
Tiziana Life Sciences (TLSA) announced that Gabriele Cerrone, the Executive Chairman, increased his shareholding by purchasing 60,000 ordinary shares at 55p each, elevating his total stake from 34.208% to 34.238%. This acquisition occurred on October 4, 2021, and is in line with the UK Takeover Code's regulations. Tiziana focuses on innovative therapeutic developments for conditions including oncology and autoimmune diseases, with upcoming Phase 2 studies for Foralumab in Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the court's sanction of its scheme to reorganize into Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. The scheme, effective on 20 October 2021, includes a two-for-one share consolidation to enhance share value comparability on NASDAQ. Key dates include the last dealings in Old Tiziana shares on 20 October 2021 and trading commencement for New Tiziana shares on 21 October 2021. The company remains focused on developing therapeutics for oncology, inflammation, and infectious diseases.
Tiziana Life Sciences (Nasdaq: TLSA) recently reported that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 100,000 ordinary shares at 52p each. This purchase increased Cerrone's ownership from 34.078% to 34.129%, just above the 1% threshold set by the UK Takeover Code. Tiziana Life Sciences, focused on innovative therapeutics for oncology and inflammatory diseases, is set to initiate Phase 2 studies for its anti-CD3 monoclonal antibody, Foralumab, for treating Crohn's Disease and multiple sclerosis, furthering its pipeline of treatment options.
Tiziana Life Sciences Plc has initiated a strategic restructuring, transitioning to Tiziana Life Sciences Ltd, a Bermuda-based parent company. This move was approved by Scheme Shareholders with 99.11% support at the Court Meeting and a requisite majority at the General Meeting. The Scheme is pending court sanction on October 19, 2021, with an expected effective date of October 21, 2021. The transition will involve the delisting of Old Tiziana shares from the London Stock Exchange and NASDAQ, paving the way for trading of New Tiziana shares.
Tiziana Life Sciences (NASDAQ: TLSA) announced its interim results for the six months ending June 30, 2021, highlighting significant advancements in therapeutic clinical programs. The Phase 1 study of Foralumab demonstrated immunomodulatory effects, while a study in Brazil showed promising outcomes for COVID-19 patients. The company signed an agreement for a Phase 2 study in severe COVID-19 cases and initiated a study for multiple sclerosis. Financially, Tiziana reported a loss of £12.59 million, with R&D expenses increasing to £12.6 million. The firm had cash reserves of £38.6 million at the period's end.
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) will host a conference call on September 8, 2021, at 4:15 p.m. ET to discuss its exclusive license agreement for evaluating Foralumab, a novel anti-CD3 monoclonal antibody, alongside CAR T candidates for cancer treatment. Interested parties can join via a toll-free line or webcast. A replay will be available until September 22, 2021. Foralumab is recognized for its safety profile in treating autoimmune diseases, making it a significant development in biotechnology.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
What is Tiziana Life Sciences Ltd. specialized in?
What are the key compounds in Tiziana's pipeline?
What recent clinical results has Tiziana announced?
Who are Tiziana Life Sciences' key partners?
What diseases are targeted by Foralumab?
What is unique about Tiziana’s drug delivery approach?
What is the status of Milciclib's clinical development?
Who leads Tiziana Life Sciences?
What is the significance of Tiziana's Expanded Access Program?
How does Tiziana Life Sciences contribute to biopharmaceutical research?
